Medical Radiology and Radiation Safety. 2023. Vol. 68. № 6

DOI:10.33266/1024-6177-2023-68-6-92-98

T.F. Malivanova, T.A. Astrelina, I.V. Kobzeva, V.A. Nikitina, Y.B. Suchkova,
A.I. Golovkova, A.S. Ostashkin, D.Y. Usupzhanova, V.A. Brunchukov,
A.A. Rastorgueva, E.I. Dobrovolskaya, A.P. Kirilchev, M.Yu. Sukhova,
O.G. Mikhadarkina, N.V. Sokolova, A.S. Samoilov

Features of the Systemic Response to Adjuvant Radiation Therapy
in Carriers of Polymorphism -308(G/A)TNF in Breast Cancer Patients

A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia

Contact person: Tatyana Feodorovna Malivanova, e-mail: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.

ABSTRACT

Background: Adjuvant radiation therapy (ART), an integral part of locoregional breast cance (BC) therapy, acting not only locally, but also systemically and leads to a shift in homeostasis, which is reflected in routine general clinical tests. Tumor necrosis factor (TNF) is a proinflammatory cytokine, the production of which can be influenced by the single-nucleotide substitution -308(G/A)TNF. The minor allele -308A can be included in the stable inherited haplotype AH8.1 of the HLA gene complex. At the same time, the carriage of the -308A without the AH8.1 haplotype is associated with a poor prognosis in patients with BC. The aim of the study was to evaluate the features of the systemic response to the course of ART in carriers of TNF-associated genotypes with BC.

Material and methods: The sample is represented by 147 BC patients who underwent a course of ART (2 Gy in 25 fractions). Clinical and morphological characteristics and data of general clinical blood analysis were obtained from medical histories. Venous blood samples for the study were obtained at the beginning and at the end of the ART course. Alleles -308(G/A)TNF and marker alleles of haplotype AH8.1 (HLA-A×01, HLA-B×08 and HLA-DRB1×03) were determined by allele-specific PCR. sTNF concentrations were determined by the ELISA in 102 blood plasma samples.

Results: TNF-associated comparison groups were identified based on genotyping: (1) 114 carriers -308GG of the TNF gene, regardless of the AH8.1 haplotype (77,6 %); (2) 23 carrier -308A(AH8.1pos) had at least one AH8.1 marker allele (15.6 %); (3) 10 carriers -308A(AH8.1neg) did not have any AH8.1 marker allele (6.8 %). In the -308A(AH8.1neg) group the average concentration of sTNF both at the beginning and at the end of ART was significantly higher and, unlike other comparison groups, did not significantly decrease at the end of the ART course. A significant decrease in absolute values was revealed during ART in a number of cases for leukocytes, platelets and lymphocytes, however within the reference values. In the group -308A(AH8.1neg) correlation analysis revealed a high strength of positive connections between sTNF and leukocytes (r=0.71; p=0.027), platelets (r=0.67; p=0.04), neutrophils (r=0.70; p=0.027) only at the end of ART, whereas at the beginning ART these correlations were weak (r≤0.3) and statistically unreliable. For other genetic groups, the revealed correlations were not strong enough.

Conclusion: The revealed features of the systemic response to ART for carriers of a prognostically unfavorable genotype -308A(AH8.1neg) – a high concentration of sTNF and a positive correlation with the content of leukocytes (probably due to neutrophils) and platelets – can be considered as targets of individualized therapy.

Keywords: breast cancer, adjuvant radiation therapy, tumor necrosis factor, genomic polymorphism

For citation: Malivanova TF, Astrelina TA, Kobzeva IV, Nikitina VA, Suchkova YB, Golovkova AI, Ostashkin AS, Usupzhanova DY, Brunchukov VA, Rastorgueva AA, Dobrovolskaya EI, Kirilchev AP, Sukhova MYu, Mikhadarkina OG, Sokolova NV, Samoilov AS. Features of the Systemic Response to Adjuvant Radiation Therapy in Carriers of Polymorphism -308(G/A)TNF in Breast Cancer Patients. Medical Radiology and Radiation Safety. 2023;68(6):92–98. (In Russian). DOI:10.33266/1024-6177-2023-68-6-92-98

References

1. Brandmaier A., Formenti S.C. The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity. Semin Radiat Oncol. 2020;30;2:139-144. https://doi.org/10.1016/j.semradonc.2019.12.005. 

2. Jatoi I., Benson J.R., Kunkler I. Hypothesis: Can the Abscopal Effect Explain the Impact of Adjuvant Radiotherapy on Breast Cancer Mortality? NPJ Breast Cancer. 2018;4:8. https://doi.org/10.1038/s41523-018-0061-y.

3. Cho U., Park H.S., Im S.Y., Yoo C.Y., Jung J.H., Suh Y.J., et al. Prognostic Value of Systemic Inflammatory Markers and Development of a Nomogram in Breast Cancer. PLoS ONE. 2018;13;7:e0200936. https://doi.org/10.1371/journal. pone.0200936.

4. Holbrook J., Lara-Reyna S., Jarosz-Griffiths H., McDermott M.F. Tumour Necrosis Factor Signalling in Health and Disease F1000Research. 2019;8;F1000 Faculty Rev:111. https://doi.org/10.12688/f1000research.17023.1.

5. Karimi M., Goldie L.C., Cruickshank M.N., Moses E.K., Abraham L.J. A Critical Assessment of the Factors Affecting Reporter Gene Assays for Promoter SNP Function: a Reassessment of -308 TNF Polymorphism Function Using a Novel Integrated Reporter System. Eur. J. Hum. Genet. 2009;17;11:1454-62. https://doi.org/10.1038/ejhg.2009.80.

6. Aly T.A., Eller E., Ide A., Gowan K., Babu S.R., Erlich H.A., Rewers M.J., Eisenbarth G.S., Fain P.R. Multi-SNP Analysis of MHC Region: Remarkable Conservation of HLA-A1-B8-DR3 Haplotype. Diabetes. 2006;55;5:1265-1269. https://doi.org/10.2337/db05-1276.  

7. Malivanova T.F., Alferova E.V., Ostashkin A.S., et al. The Overall Survival of Breast Cancer Patients Depends on a Combination of Polymorphisms of Tumor Necrosis Factor Gene and HLA Haplotypes. Mol. Genet. Microbiol. Virol. 2020;35:38–46. https://doi.org/10.3103/S0891416820010061.

8. Cruceriu D., Baldasici O., Balacescu O., Berindan-Neagoe I. The Dual Role of Tumor Necrosis Factor-Alpha (TNF-α) in Breast Cancer: Molecular Insights and Therapeutic Approaches. Review Cell Oncol (Dordr). 2020;43;1:1-18. https://doi.org/10.1007/s13402-019-00489-1.

9. Маливанова Т.Ф., Астрелина Т.А., Кобзева И.В., Никитина В.А., Сучкова Ю.Б., Осташкин А.С., Усупжанова Д.Ю., Добровольская Е.И., Брунчуков В.А., Расторгуева А.А., Ломоносова Е.Е., Любаева Е.С., Кретова Е.Ю., Степанянц Н.Г., Сухова М.Ю., Самойлов А.С. Аутоиммунный гаплотип AH8.1 нормализует уровень фактора некроза опухоли в сыворотках крови больных раком молочной железы // Молекулярная генетика, микробиология и вирусология. 2023. Т.41, № 1. С. 38 45. [Malivanova T.F., Astrelina T.A., Kobzeva I.V., Nikitina VA, Suchkova YuB, Ostashkin AS, Usupzhanova DYu, Brunchukov VA, Dobrovolskaya EI, Rastorgueva AA, Lomonosova EE, Lubaeva ES, Kretova EYu, Stepanyants NG, Sukhova MYu, Samoylov AS. Autoimmune Haplotype AH8.1 Normalizes the Level of Tumor Necrosis Factor in the Blood Sera of Breast Cancer Patients. Molekulyarnaya Genetika, Mikrobiologiya i Virusologiya = Molecular Genetics, Microbiology and Virology. 2023;41;1:38-45 (In Russ.). https://doi.org/10.17116/molgen20234101138].  

10. Bower J.E., Ganz P.A., Irwin M.R., Cole S.W., et al. Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients. JNCI Cancer Spectr. 2022;6;4:pkac052. https://doi.org/10.1093/jncics/pkac052.

11. Chen F., Jin J.-Y., Hui T.S.K., Jing H., Zhang H., Nong Y., Han Y., Wang W., Ma L., Yi F., Chen Q., Zhang Y., Fu P., Yang L., Xu Z., Kong F.-M.S. Radiation Induced Lymphopenia Is Associated with the Effective Dose to the Circulating Immune Cells in Breast Cancer. Front. Oncol. 2022;12:768956. https://doi.org/10.3389/fonc.2022.76895.

12. Singh S., Sharma A., Arora S.K. High Producer Haplotype (CAG) of -863C/A, -308G/A and -238G/A Polymorphisms in the Promoter Region of TNF-a Gene Associate with Enhanced Apoptosis of Lymphocytes in HIV-1 Subtype C Infected Individuals from North India. PLoS ONE. 2014;9;5:e98020. https://doi.org/10.1371/journal. pone.0098020.

13. Shirmohammadi E., Ebrahimi S.S., Farshchi A., Salimi M. The Efficacy of Etanercept as Anti-Breast Cancer Treatment Is Attenuated by Residing Macrophages. BMC Cancer. 2020;20;1:836. https://doi.org/10.1186/s12885-020-07228-y.

14. Lewin N.L., Luetragoon T., Shamoun L., Oliva D., et al. The Influence of Adjuvant Radiotherapy and Single Nucleotide Polymorphisms on Circulating Immune Response Cell Numbers and Phenotypes of Patients with Breast Cancer. Anticancer Res. 2019;39;9.:4957-4963. https://doi.org/10.21873/anticanres.13684.

15. Kaur S., Singh A., Kaur J., Verma N., et al. Upregulation of Cytokine Signalling in Platelets Increases Risk of Thrombophilia in Severe COVID-19 Patients. Blood Cells Mol. Dis. 2022;94:102653. https://doi.org/10.1016/j.bcmd.2022.102653.

16. Wang L., Wang X., Guo E., Mao X., Miao S. Emerging Roles of Platelets in Cancer Biology and Their Potential as Therapeutic Targets. Front. Oncol. 2022;12:939089. https://doi.org/10.3389/fonc.2022.939089.

17. Qian H., Chen R., Wang B., Yuan X., Chen S., Liu Y., Shi G. Associations of Platelet Count with Inflammation and Response to Anti TNF-α Therapy in Patients with Ankylosing Spondylitis. Front. Pharmacol. 2020;11:559593. https://doi.org/10.3389/fphar.2020.559593.

18. Shang Y., Sun J., Wu X., Wang Q. Activated Platelet Membrane Nanovesicles Recruit Neutrophils to Exert the Antitumor Efficiency. Front. Chem. 2022;10:955995. https://doi.org/10.3389/fchem.2022.955995. 

19. Neuenfeldt F., Schumacher J.C., Grieshaber-Bouyer R., Habicht J., et al. Inflammation Induces Pro-NETotic Neutrophils Via TNFR2 Signaling. Cell Rep. 2022;39;3:110710. https://doi.org/10.1016/j.celrep.2022.110710.

20. Snoderly H.T., Boone B.A., Bennewitz M.F. Neutrophil Extracellular Traps in Breast Cancer and Beyond: Current Perspectives on NET Stimuli, Thrombosis and Metastasis, and Clinical Utility for Diagnosis and Treatment. Breast Cancer Res. 2019;21;1:145. https://doi.org/10.1186/s13058-019-1237-6.

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study was carried out with the financial support of the Federal Target Program “Ensuring Nuclear and Radiation Safety for 2016-2020 and for the period up to 2035”.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.07.2023. Accepted for publication: 27.08.2023.